§ Federal grant opportunity · PAR-25-159
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)
National Institutes of Health is accepting applications for Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional). The deadline is January 7, 2027 and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- January 7, 2027
- Award range
- Award amount not published
- Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- PAR-25-159
Program overview
This Notice of Funding Opportunity (NOFO) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider NOFO (TEMP-23833, the R61/R33 option).
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before January 7, 2027, allowing time for registration and validation.
Related grant opportunities
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
- Accelerating Solutions to Improve Access and Quality of Empirically-Supported Practices for Youth Mental Health (R01 Clinical Trial Optional)
- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.